Loading patent…
AssigneeThe Government of the United States of America as represented by the Secretary of the Department of
InventorsDan T. Stinchcomb, Claire Kinney, Richard M. Kinney, Jill A. Livengood
Estimating the term…
Embodiments herein report compositions, uses and manufacturing of dengue virus constructs and live attenuated dengue viruses. Some embodiments concern a composition that includes, but is not limited to, a tetravalent dengue virus composition. In certain embodiments, compositions can include constructs of one or more serotypes of dengue virus, such as dengue-1 (DEN-1) virus, dengue-2 (DEN-2) virus, dengue-3 (DEN-3) or dengue-4 (DEN-4) virus constructs. In other embodiments, constructs disclosed herein can be combined in a composition to generate a vaccine against more one or more dengue virus constructs that may or may not be subsequently passaged in mammalian cells.
A nucleic acid chimera comprising a nucleic acid sequence encoding a polypeptide comprising a dengue-1/dengue-2 chimera represented by SEQ ID NO:1 (Pre-master), SEQ ID NO:3 (MVS), SEQ ID NO.5 (WVS), SEQ ID NO:7 (BVS) or a combination thereof.
A polypeptide molecule encoded by a nucleic acid sequence encoding a dengue-1/dengue-2 chimera represented by SEQ ID NO:2 (Pre-master), SEQ ID NO:4 (MVS), SEQ ID NO:6 (WVS), SEQ ID NO:8 (BVS) or a combination thereof.
A nucleic acid sequence comprising a nucleic acid sequence encoding a modified live, attenuated dengue-2 virus represented by SEQ ID NO:9 (Pre-master), SEQ ID NO:11 (MVS), SEQ ID NO:13 (WVS), SEQ ID NO:15 (BVS) or a combination thereof.
A polypeptide molecule encoded by a nucleic acid sequence encoding a live, attenuated dengue-2 virus represented by SEQ ID NO:12 (MVS), SEQ ID NO:14 (WVS), SEQ ID NO:16 (BVS) or a combination thereof.
15-28. (canceled)
An immunogenic composition comprising one or more live, attenuated dengue viruses having a nucleotide sequence encoding a dengue virus or dengue virus chimera represented by SEQ ID NOS:
A live, attenuated dengue-1 chimeric virus comprising one or more polypeptide sequences encoded from one or more nucleic acid sequences represented by SEQ ID NO:1 (Pre-master), SEQ ID NO:3 (MVS), SEQ ID NO:5 (WVS), SEQ ID NO:7 (BVS) or a combination thereof, wherein one or more of the nucleic acid sequences are encapsidated.
A live, attenuated dengue-2 virus comprising one or more polypeptide sequences encoded from one or more nucleic acid sequences comprising SEQ ID NO:9 (Pre-master), SEQ ID NO:11 (MVS), SEQ ID NO:13 (WVS), SEQ ID NO:15 (BVS) or a combination thereof, wherein one or more of the nucleic acid sequences are encapsidated.
38-39. (canceled)
A nucleic acid dengue-1 chimera comprising nucleic acid sequences represented by SEQ ID NO:7 encoding a mixture of species containing nucleotides C and G at nucleotide position 2384 which encodes a mixture of dengue viral species containing amino acids Gly and Ala at amino acid position 483.
A dengue-2 nucleic acid sequence comprising nucleic acid sequences represented by SEQ ID NO:15 encoding a mixture of species containing nucleotides G and C at nucleotide position 6481 which encodes a mixture of dengue viral species containing amino acids Ala and Pro in NS4A-36.
A dengue-2 nucleic acid sequence comprising nucleic acid sequences represented by SEQ ID NO:15 encoding a mixture of species containing nucleotides C and T at nucleotide position 7156 which encodes a mixture of dengue viral species containing Leu and Phe in NS4B-111.
44-45. (canceled)
Dependencies are inferred from the claim text.